Search clinical trials for: Roflumilast 250Mcg Tab

Total 6194 results

GlaxoSmithKline

Completed

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Romania, Bulgaria, Argentina, Canada, Chile, Philippines, South Africa, Thailand, Netherlands, Korea, Republic of, Hungary, United Kingdom
Sadat City University

Recruiting

The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients

Major Depressive Disorder

Egypt
Theravance Biopharma
GlaxoSmithKline

Completed

Study of GSK961081 in Healthy Volunteer Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

GSK BHR Study (Sont - Second Study)

Asthma

United States, Bulgaria, Puerto Rico, Brazil
GlaxoSmithKline

Completed

GSK BHR Study (Sont)

Asthma

United States, Latvia, Puerto Rico, Brazil
GlaxoSmithKline

Completed

28-day Repeat Dose Study of GSK573719

Pulmonary Disease, Chronic Obstructive

United States, Estonia, Germany, Poland
GlaxoSmithKline

Completed

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.

Asthma

United States, Australia, Germany, Russian Federation, Bulgaria, Canada, Chile, Peru, Philippines, South Africa, Thailand, Mexico, Israel, Ukraine, New Zealand, Croatia
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
The First Affiliated Hospital with Nanjing Medical University; Cancer Institute... and other collaborators

Unknown

Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia (PEG-rhG-CSF)

Neutropenia

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of SYHA1402 in Healthy Subjects

Diabetic Peripheral Neuropathy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People

Diabetic Neuropathy Peripheral

China
HK inno.N Corporation

Enrolling by invitation

PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects

Healthy

Korea, Republic of
Professor Fernando Figueira Integral Medicine Institute

Completed

Dose Comparison of Misoprostol for Cervix Ripening Before Operative Hysteroscopy.

Cervix; Open

Brazil
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV

Hiv

United States
Shire

Completed

Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism (PARALLAX)

Hypoparathyroidism

United States, Hungary, Canada, Denmark
Hospital de Clinicas de Porto Alegre

Completed

Misoprostol 400 µg Versus 200 µg for Cervical Ripening in 1st Trimester Miscarriage (MISO200)

Miscarriage in First Trimester

Brazil
Hanlim Pharm. Co., Ltd.

Recruiting

Phase 4 Study to Evaluate Efficacy and Safety of Entelon Tab.150mg in Patients With Chronic Venous Disease(CVD)

Chronic Venous Disease

Korea, Republic of
GlaxoSmithKline

Completed

Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers

Irritable Bowel Syndrome (IBS) | Irritable Colon

United States
University of Miami
Forest Laboratories

Completed

Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD

COPD

United States
HK inno.N Corporation

Completed

PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers

Healthy

Korea, Republic of
HK inno.N Corporation

Completed

Study to Evaluate the Pharmacokinetic Characteristics and Safety of IN-C004 in Healthy Volunteers

Healthy

Korea, Republic of
GlaxoSmithKline

Completed

Study to Evaluate the Pharmacokinetic Profile of Salbutamol Delivered by Unit Dose Dry Powder Inhaler (UD-DPI) Compared to the Diskus and Metered Dose Inhaler (MDI) in Healthy Volunteers.

Asthma

Australia
Universitaire Ziekenhuizen KU Leuven

Completed

The Influence of Sweet Substrates on Hunger, Gastrointestinal Hormones and the Migrating Motor Complex

Healthy
Asan Medical Center

Unknown

Strategy to Improve Adherence of Roflumilast

Chronic Obstructive Pulmonary Disease

Korea, Republic of
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Study of Tolerability, Safety, and Pharmacokinetics of ZL-82 in Healthy Adult Subjects.

Rheumatoid Arthritis (RA) | Inflammatory Bowel Disease - IBD1

China
YD Global Life Science Co., Ltd.

Unknown

The Study to YD312 Tablet in Patients With Diabetic Macular Edema

Diabetic Macular Edema(DME)

United States, Korea, Republic of
GlaxoSmithKline

Completed

A Healthy Volunteer Study With Inhaled GSK573719 and Placebo

Pulmonary Disease, Chronic Obstructive

Belgium
Arcutis Biotherapeutics, Inc.

Completed

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)

Atopic Dermatitis Eczema

United States, Canada
FLUIDDA nv

Terminated

Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging

Pulmonary Disease, Chronic Obstructive

Belgium
OrthoTrophix, Inc

Completed

A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees

Knee Osteoarthritis

United States
AstraZeneca

Completed

OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)

Chronic Obstructive Pulmonary Disease | COPD

United States, France, Poland, South Africa, Canada, Germany
AstraZeneca

Completed

The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)

Chronic Obstructive Pulmonary Disease, COPD

France, Poland, South Africa, Spain, United States, Canada, United Kingdom
AstraZeneca

Completed

Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)

Asthma

United States, Argentina, Colombia, Mexico, Peru
Seoul National University Bundang Hospital

Unknown

Phase2, Single Group, Open Clinical Trial to Evaluate the Efficacy and Safety of Roflumilast in Symptomatic Bronchiectasis Patients

Symptomatic Bronchiectasis

Korea, Republic of
AstraZeneca

Completed

Long-term Observational Study of the Safety of Roflumilast

COPD

Sweden, Germany, United States, Norway
AstraZeneca

Completed

The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)

Asthma

United States, Russian Federation, Ukraine
AstraZeneca

Completed

Pharmacokinetic Study of Single and Repeated Dose of Roflumilast 500 µg , in Healthy Chinese Subjects

Chronic Obstructive Pulmonary Disease

China
AstraZeneca

Completed

Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study (FORTUNA)

Diabetes Mellitus Type 2
Daewoong Bio Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of rhEGF Eye Drops in Healthy Male Subjects

Dry Eye Syndromes

Korea, Republic of
FLUIDDA nv

Completed

Evaluation With CT Scan of Possible Changes in Airways After Treatment With Daxas® in Severe Chronic Obstructive Pulmonary Disease Patients

Pulmonary Disease, Chronic Obstructive

Belgium
GlaxoSmithKline

Completed

A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Estonia, Canada, Chile, Germany, Peru, Philippines, Mexico, Korea, Republic of, Denmark, Russian Federation, Poland, Slovakia
AstraZeneca
Pfizer

Completed

Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)

Asthma

United States, Austria, Croatia, Czech Republic, Finland, France, Greece, Hungary, India, Ireland, Italy, New Zealand, Norway, Pakistan, Philippines, Poland, Portugal, Russian Federation, Singapore, South Africa, Spain, Taiwan, Thai... and more
AstraZeneca

Completed

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)

Chronic Obstructive Pulmonary Disease | COPD

Austria, France, Hungary, Italy, Poland, Portugal, Russian Federation, South Africa, Spain, Canada, United Kingdom, Australia, Netherlands, Switzerland
AstraZeneca

Completed

Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

Chronic Obstructive Pulmonary Disease | COPD

United States, Argentina, Canada, Colombia, Mexico, Peru
AstraZeneca

Completed

Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015)

Asthma

France, South Africa, Spain, Australia, Belgium
University of California, Davis

Terminated

Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma

Asthma

United States
Bispebjerg Hospital

Completed

Efficacy of Roflumilast in the Treatment of Psoriasis (PSORRO)

Psoriasis

Denmark
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Terminated

A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients

Chronic Obstructive Pulmonary Disease

China
AstraZeneca

Completed

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)

Chronic Obstructive Pulmonary Disease (COPD)

France, Germany, United Kingdom, United States, Australia, Austria, Brazil, Hungary, New Zealand, Romania, Russian Federation
AstraZeneca

Completed

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS) (REACT)

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Austria, Belgium, Germany, Greece, Russian Federation, Australia, Brazil, Canada, Denmark, France, Hungary, Israel, Italy, Netherlands, Poland, Slovakia, South Africa, Spain, Turkey, United Kingdom
AstraZeneca

Completed

Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)

COPD

Korea, Republic of, Malaysia, Taiwan, Hong Kong, Philippines

Search clinical trials for: Roflumilast 250Mcg Tab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations